1
|
Gutiérrez Salmeán G, Delgadillo González M, Rueda Escalona AA, Leyva Islas JA, Castro-Eguiluz D. Effects of prebiotics, probiotics, and synbiotics on the prevention and treatment of cervical cancer: Mexican consensus and recommendations. Front Oncol 2024; 14:1383258. [PMID: 38606098 PMCID: PMC11007160 DOI: 10.3389/fonc.2024.1383258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 03/18/2024] [Indexed: 04/13/2024] Open
Abstract
Gut microbiota plays a crucial role in modulating immune responses, including effector response to infection and surveillance of tumors. This article summarizes the current scientific evidence on the effects of supplementation with prebiotics, probiotics, and synbiotics on high-risk human papillomavirus (HPV) infections, precancerous lesions, and various stages of cervical cancer development and treatment while also examining the underlying molecular pathways involved. Our findings indicate that a higher dietary fiber intake is associated with a reduced risk of HPV infection, while certain probiotics have shown promising results in clearing HPV-related lesions. Additionally, certain strains of probiotics, prebiotics such as inulin and fructo-oligosaccharides, and synbiotics decrease the frequency of gastrointestinal adverse effects in cervical cancer patients. These agents attain their results by modulating crucial metabolic pathways, including the reduction of inflammation and oxidative stress, promoting apoptosis, inhibiting cell proliferation, and suppressing the activity of oncogenes, thus attenuating tumorigenesis. We conclude that although further human studies are necessary, robust evidence in preclinical models demonstrates that prebiotics, probiotics, and synbiotics play an essential role in cervical cancer, from infection to carcinogenesis and its medical treatment. Consequently, we strongly recommend conducting high-quality clinical trials using these agents as adjuvants since they have proven safe.
Collapse
Affiliation(s)
- Gabriela Gutiérrez Salmeán
- Centro de Investigación en Ciencias de la Salud (CICSA), Facultad de Ciencias de la Salud, Universidad Anáhuac Mexico, Huixquilucan, Estado de Mexico, Mexico
- Servicio de Nutrición, Centro de Especialidades del Riñón (CER), Naucalpan de Juarez, Estado de Mexico, Mexico
| | - Merari Delgadillo González
- Modelo Integral para la atención del Cáncer Cervicouterino Localmente Avanzado y Avanzado (MICAELA) Program, Instituto Nacional de Cancerología, Mexico City, Mexico
| | | | - José Antonio Leyva Islas
- Nutritional and Metabolic Support, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) Hospital Regional Lic. Adolfo López Mateos, Mexico City, Mexico
| | - Denisse Castro-Eguiluz
- Investigador por México, Consejo Nacional de Humanidades Ciencias y Tecnologías (CONAHCyT)—Department of Clinical Research, Instituto Nacional de Cancerología, Mexico City, Mexico
| |
Collapse
|
2
|
Di W, Li X, Yang Q. Polysaccharide of Lactobacillus casei SB27 reduced colon cancer cell prognosis through mitochondrial damage by upregulation of HINT2. Asia Pac J Clin Oncol 2023; 19:e248-e257. [PMID: 36271660 DOI: 10.1111/ajco.13876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Revised: 07/13/2022] [Accepted: 09/25/2022] [Indexed: 12/01/2022]
Abstract
AIMS Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. This study aimed to explore the effects of Polysaccharide of Lactobacillus casei SB27 in colon cancer and its possible mechanisms. METHODS Colon cancer was induced by giving dextran sulfate sodium and Azoxymethane. Uman Colon Cancer Cell Line (HCT)-116 cells were used to vitro model in this experiment. RESULTS Polysaccharide of L. casei SB27 reduced colon cancer in azoxymethane-dextran sulfate sodium (AOM+DSS)-induced mice. Polysaccharide of L. casei SB27 reduced colon cancer prognosis in vitro model. Polysaccharide of L. casei SB27 reduced short chain fatty acids by Bacillus coli. Polysaccharide of L. casei promoted mitochondrial damage by Calcium ion entry. Polysaccharide of L. casei induced histidine nucleotide binding protein 2/mitochondrial calcium uniporter (HINT2/MCU) signaling pathway. Immunocoprecipitation (IP) showed that HINT2 protein interlinked MCU protein. Polysaccharide of L. casei suppressed HINT2 ubiquitination. The regulation of HINT2 affected the effects of L. casei polysaccharide on colon cancer prognosis and mitochondrial damage by Calcium ion entry in vitro model. CONCLUSION In conclusion, the present report demonstrated that polysaccharide of L. casei SB27 reduced colon cancer cell prognosis through mitochondrial damage by upregulation of HINT2. Polysaccharide of L. casei SB27 might be used for colon cancer treatment and could be helpful for personalized treatment.
Collapse
Affiliation(s)
- Wei Di
- School of Food Biology, Guangdong Polytechnic of Science and Trade, Guangzhou, China
| | - Xin Li
- School of Food Biology, Guangdong Polytechnic of Science and Trade, Guangzhou, China
| | - Qiaoyi Yang
- School of Food Biology, Guangdong Polytechnic of Science and Trade, Guangzhou, China
| |
Collapse
|
3
|
Ren J, Li H, Zeng G, Pang B, Wang Q, Wei J. Gut microbiome-mediated mechanisms in aging-related diseases: are probiotics ready for prime time? Front Pharmacol 2023; 14:1178596. [PMID: 37324466 PMCID: PMC10267478 DOI: 10.3389/fphar.2023.1178596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Accepted: 05/24/2023] [Indexed: 06/17/2023] Open
Abstract
Chronic low-grade inflammation affects health and is associated with aging and age-related diseases. Dysregulation of the gut flora is an important trigger for chronic low-grade inflammation. Changes in the composition of the gut flora and exposure to related metabolites have an effect on the inflammatory system of the host. This results in the development of crosstalk between the gut barrier and immune system, contributing to chronic low-grade inflammation and impairment of health. Probiotics can increase the diversity of gut microbiota, protect the gut barrier, and regulate gut immunity, thereby reducing inflammation. Therefore, the use of probiotics is a promising strategy for the beneficial immunomodulation and protection of the gut barrier through gut microbiota. These processes might positively influence inflammatory diseases, which are common in the elderly.
Collapse
Affiliation(s)
- Jing Ren
- Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- Graduate School of Beijing University of Chinese Medicine, Beijing, China
| | - Huimin Li
- Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Guixing Zeng
- Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Boxian Pang
- Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- Graduate School of Beijing University of Chinese Medicine, Beijing, China
| | - Qiuhong Wang
- Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Junping Wei
- Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| |
Collapse
|
4
|
Liu P, Lu Y, Li R, Chen X. Use of probiotic lactobacilli in the treatment of vaginal infections: In vitro and in vivo investigations. Front Cell Infect Microbiol 2023; 13:1153894. [PMID: 37077531 PMCID: PMC10106725 DOI: 10.3389/fcimb.2023.1153894] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 03/23/2023] [Indexed: 04/05/2023] Open
Abstract
The vaginal microbiome is a distinct component of the human microbiome that is colonized by a wide variety of microorganisms. Lactobacilli are the most frequently identified microorganisms in the healthy human vagina. These Gram-positive bacilli can acidify the vaginal microenvironment, inhibit the proliferation of other pathogenic microorganisms, and promote the maintenance of a eubiotic vaginal microbiome. However, a vaginal flora with a reduced proportion or abundance of lactobacilli is associated with various vaginal infections that have been linked to serious health consequences such as infertility, preterm birth, pelvic inflammatory disease, premature rupture of membranes, and miscarriage. Due to their “Generally Recognized as Safe” classification and critical role in vaginal health, probiotic lactobacilli have been widely used as an alternative or adjunct to traditional antibiotic therapy for the treatment of vaginal infections and restoration of the vaginal microbiome. This review focuses on the significant role of probiotic lactobacilli in the vaginal microenvironment and discusses the use of probiotic lactobacilli in the treatment of female vaginal infections in vitro and in vivo.
Collapse
Affiliation(s)
| | | | - Rongguo Li
- *Correspondence: Rongguo Li, ; Xiaodi Chen,
| | | |
Collapse
|
5
|
Haghighi D, Yazdani S, Farzanehpour M, Esmaeili Gouvarchinghaleh H. Combined extract of heated TC1, a heat-killed preparation of Lactobacillus casei and alpha-galactosyl ceramide in a mouse model of cervical cancer. Infect Agent Cancer 2022; 17:51. [PMID: 36127698 PMCID: PMC9487028 DOI: 10.1186/s13027-022-00464-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 09/14/2022] [Indexed: 12/02/2022] Open
Abstract
Background Nowadays, cancer is the leading cause of death among threats to humanity, necessitating prompt action and preparation. Cervical cancer is one of the most common cancers in women and is currently treated with surgery, radiation, chemotherapy, and immunotherapy, among other treatments. Current oncology approaches focused on the simultaneous development of safe and effective cancer multi-agent therapies. The present study aimed to evaluate the effects of a combined extracts of heated TC1, a heat-killed preparation of Lactobacilluscasei, and alpha-galactosyl ceramide (α-GalCer) in a mouse model of cervical cancer. Material and methods Cervical cancer in the mouse model was prepared by TC1 cells subcutaneous injection into the left flank of female C57BL/6 mouse aged 6–8 weeks (n = 80). After the appearance of the palpable tumor, the mice with cervical cancer were randomly devoted to 8 (ten-member) groups. The mice in some groups were treated with PBS, TC1 cell extract, L. casei extract, α-GalCer, and a combination of the mentioned treatments. Then, they were evaluated the splenocytes proliferation, lactate dehydrogenase production and nitric oxide. Moreover, IL-4, IFN-γ, and TGF-β cytokine levels of splenocytes supernatant the mice were measured. In all evaluations, a statistical difference of less than 0.05 (P ˂ 0.05) was considered as a significant level. Result The findings revealed that the combination therapy group (heated TC1 cell and L. casei extracts with α-GalCer) significantly increases the splenocytes proliferation (MTT) (0.358 ± 0.04 OD), LDH production (45.9 ± 2.3 U/L), NO rate (38.4 ± 2.8 µM), and IFN-γ cytokine level (46.6 ± 3.7 pg/ml) (P < 0.05). Also, observes a significantly reduces the production of IL-4 (11.6 ± 2.5 pg/ml) and TGF-β cytokines levels (7.8 ± 2.5 pg/ml) (P < 0.05) in comparison to the control group. Conclusion The study showed that combination therapy of L. casei and α-GalCer is an efficient treatment for cervical cancer in the mouse model.
Collapse
Affiliation(s)
- Dorsa Haghighi
- Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Shaghayegh Yazdani
- Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.,Department of Microbiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Mahdieh Farzanehpour
- Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | | |
Collapse
|
6
|
Cavallari EN, Ceccarelli G, Santinelli L, Innocenti GP, De Girolamo G, Borrazzo C, Spagnolello O, Scagnolari C, Arcieri S, Ciardi A, Pierangeli A, Mastroianni CM, d’Ettorre G. Clinical Effects of Oral Bacteriotherapy on Anal HPV Infection and Related Dysplasia in HIV-Positive MSM: Results from the "HPVinHIV" Trial. Biomedicines 2021; 9:biomedicines9111738. [PMID: 34829967 PMCID: PMC8615833 DOI: 10.3390/biomedicines9111738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 11/11/2021] [Accepted: 11/17/2021] [Indexed: 11/16/2022] Open
Abstract
Background. Anal HPV infection, anal dysplasia and, ultimately, anal cancer are particularly common in HIV-infected men who have sex with men. Treatment of anal dysplasia, aiming to prevent evolution to squamous cell carcinoma of the anus, is currently limited to direct ablation and/or application of topical therapy. The aim of the present study is to investigate the effect of oral bacteriotherapy (Vivomixx® in EU, Visbiome® in USA) on anal HPV infection and HPV-related dysplasia of the anal canal in HIV-infected men who have sex with men. Methods. In this randomized, placebo-controlled, quadruple-blinded trial (NCT04099433), HIV-positive men who have sex with men with anal HPV infection and HPV-related dysplasia were randomized to receive oral bacteriotherapy or placebo for 6 months. Anal HPV test, anal cytology and high resolution anoscopy with biopsies of anal lesions were performed at baseline and at the end of the study. Safety and tolerability of oral bacteriotherapy were also evaluated. Interim analysis results were presented. Results. 20 participants concluded the study procedures to date. No serious adverse events were reported. In respect to participants randomized to placebo, individuals in the experimental arm showed higher rate of anal dysplasia regression (p = 0.002), lower rate of onset of new anal dysplasia (p = 0.023) and lower rates of worsening of persistent lesions (p = 0.004). Clearance of anal HPV infection was more frequently observed in the bacteriotherapy group (p = 0.067). Conclusion. Being an interim analysis, we limit ourselves to report the preliminary results of the current study. We refer the conclusions relating to the possible effectiveness of the intervention to the analysis of the definitive data.
Collapse
Affiliation(s)
- Eugenio Nelson Cavallari
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, 00161 Rome, Italy
| | - Giancarlo Ceccarelli
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, 00161 Rome, Italy
- Correspondence:
| | - Letizia Santinelli
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
| | - Giuseppe Pietro Innocenti
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
| | - Gabriella De Girolamo
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, 00161 Rome, Italy
| | - Cristian Borrazzo
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
| | - Ornella Spagnolello
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
| | - Carolina Scagnolari
- Department of Molecular Medicine, “Sapienza” University of Rome, 00161 Rome, Italy; (C.S.); (A.P.)
| | - Stefano Arcieri
- Department of Surgical Sciences, “Sapienza” University of Rome, 00161 Rome, Italy;
| | - Antonio Ciardi
- Department of Radiology, Oncology and Human Pathology, “Sapienza” University of Rome, 00161 Rome, Italy;
| | - Alessandra Pierangeli
- Department of Molecular Medicine, “Sapienza” University of Rome, 00161 Rome, Italy; (C.S.); (A.P.)
| | - Claudio Maria Mastroianni
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, 00161 Rome, Italy
| | - Gabriella d’Ettorre
- Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, 00161 Rome, Italy; (E.N.C.); (L.S.); (G.P.I.); (G.D.G.); (C.B.); (O.S.); (C.M.M.); (G.d.)
- Azienda Ospedaliero-Universitaria Policlinico Umberto I, 00161 Rome, Italy
| |
Collapse
|
7
|
Youssef M, Ahmed HY, Zongo A, Korin A, Zhan F, Hady E, Umair M, Shahid Riaz Rajoka M, Xiong Y, Li B. Probiotic Supplements: Their Strategies in the Therapeutic and Prophylactic of Human Life-Threatening Diseases. Int J Mol Sci 2021; 22:11290. [PMID: 34681948 PMCID: PMC8537706 DOI: 10.3390/ijms222011290] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 10/10/2021] [Accepted: 10/13/2021] [Indexed: 12/18/2022] Open
Abstract
Chronic diseases and viral infections have threatened human life over the ages and constitute the main reason for increasing death globally. The rising burden of these diseases extends to negatively affecting the economy and trading globally, as well as daily life, which requires inexpensive, novel, and safe therapeutics. Therefore, scientists have paid close attention to probiotics as safe remedies to combat these morbidities owing to their health benefits and biotherapeutic effects. Probiotics have been broadly adopted as functional foods, nutraceuticals, and food supplements to improve human health and prevent some morbidity. Intriguingly, recent research indicates that probiotics are a promising solution for treating and prophylactic against certain dangerous diseases. Probiotics could also be associated with their essential role in animating the immune system to fight COVID-19 infection. This comprehensive review concentrates on the newest literature on probiotics and their metabolism in treating life-threatening diseases, including immune disorders, pathogens, inflammatory and allergic diseases, cancer, cardiovascular disease, gastrointestinal dysfunctions, and COVID-19 infection. The recent information in this report will particularly furnish a platform for emerging novel probiotics-based therapeutics as cheap and safe, encouraging researchers and stakeholders to develop innovative treatments based on probiotics to prevent and treat chronic and viral diseases.
Collapse
Affiliation(s)
- Mahmoud Youssef
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; (M.Y.); (A.Z.); (A.K.); (F.Z.); (E.H.)
- Food Science and Technology Department, Faculty of Agriculture, Al-Azhar University, Cairo 11651, Egypt
| | - Hanaa Y. Ahmed
- The Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo 11787, Egypt;
| | - Abel Zongo
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; (M.Y.); (A.Z.); (A.K.); (F.Z.); (E.H.)
- Biological Sciences, Food and Nutrition Research Center, Department of Biochemistry and Microbiology, University Joseph Ki-Zerbo, Ouagadougou 03 BP 7021, Burkina Faso
| | - Ali Korin
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; (M.Y.); (A.Z.); (A.K.); (F.Z.); (E.H.)
- Food Science and Technology Department, Faculty of Agriculture, Al-Azhar University, Cairo 11651, Egypt
| | - Fuchao Zhan
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; (M.Y.); (A.Z.); (A.K.); (F.Z.); (E.H.)
| | - Essam Hady
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; (M.Y.); (A.Z.); (A.K.); (F.Z.); (E.H.)
- Food Science and Technology Department, Faculty of Agriculture, Al-Azhar University, Cairo 11651, Egypt
| | - Muhammad Umair
- Department of Food Science and Engineering, College of Chemistry and Engineering, Shenzhen University, Shenzhen 518060, China; (M.U.); (M.S.R.R.)
| | - Muhammad Shahid Riaz Rajoka
- Department of Food Science and Engineering, College of Chemistry and Engineering, Shenzhen University, Shenzhen 518060, China; (M.U.); (M.S.R.R.)
| | - Yongai Xiong
- Department of Pharmaceutics, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563003, China
| | - Bin Li
- College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, China; (M.Y.); (A.Z.); (A.K.); (F.Z.); (E.H.)
| |
Collapse
|